Document Detail


Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program.
MedLine Citation:
PMID:  23202815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Untreated substance use disorders (SUD) among HIV patients contribute to worse HIV care outcomes and increased HIV transmission. Although there are clinical and policy recommendations for integrated SUD and HIV treatment, payment issues including complex funding streams are a barrier.
OBJECTIVES: We assessed the availability of guideline-concordant medication-assisted therapies to treat alcohol, tobacco, and opioid dependence on state-administered AIDS Drug Assistance Programs (ADAPs), an important source of drug coverage for low-income HIV patients. We examined which medication-assisted therapies are most likely to be included on formularies and variation of these therapies across states.
RESEARCH DESIGN: We reviewed state-specific ADAP formularies from 1997 to 2009 for the presence of guideline-concordant medication-assisted therapies to treat alcohol, tobacco, and opioid dependence.
RESULTS: The most frequently included medication-assisted therapies were those to treat tobacco dependence, followed by opioid dependence. Few states covered alcohol dependence medications. In each year, <10% of states covered all recommended medications and <50% covered a partial formulary for at least 1 SUD.
CONCLUSIONS: ADAPs could provide access to medication-assisted therapies for SUD for a significant number of HIV patients, but these medications have not been widely covered throughout the program's history. Increased availability of medication-assisted therapies through ADAP could facilitate integrated HIV and SUD care.
Authors:
Erika G Martin; Karen H Wang
Related Documents :
7060055 - Preparation of new omega-aldehydoalkyl 1-thio-d-glycopyranosides, and their coupling to...
12029285 - Oral fungal colonization and oral candidiasis in renal transplant patients: the relatio...
16469415 - Investigation on recombinant hirudin via oral route.
22809825 - On mining clinical pathway patterns from medical behaviors.
22924995 - Hippocampal agenesis in an individual who engaged in violent criminal behaviors after d...
10369615 - A comparison of antihypertensive medication utilization before and after guideline chan...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  62     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-10-21     Completed Date:  2013-10-29     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  421-9     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use
HIV Infections / complications*,  drug therapy
Humans
Substance-Related Disorders / complications,  rehabilitation*
Grant Support
ID/Acronym/Agency:
R01 MH065869/MH/NIMH NIH HHS; R01MH65869/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of long-term contraceptive promotion on incident pregnancy: a randomized controlled trial amo...
Next Document:  Valuation of green walls and green roofs as soundscape measures: including monetised amenity values ...